Reference method
Define how units are repeatedly inspected, how detection frequency is established, and how disagreements or unstable standards are handled.
Study-Specific Challenge Sets
Build a controlled challenge set for comparative inspection studies using your approved reference method, representative product and package, justified defect population, blinded coding, and site-defined decision rules.
Design Inputs
Representative standards start with the product, package, process, defect taxonomy, and intended decision. They do not start with a universal count or a generic defect list.
Define how units are repeatedly inspected, how detection frequency is established, and how disagreements or unstable standards are handled.
Use representative defect families and a justified detectability range rather than assuming one universal set size or mix.
Coding, sequence control, good-unit representation, and repeat presentations should prevent avoidable bias.
Acceptance criteria, statistical methods, invalid-run rules, and investigation triggers belong in the approved site protocol.
Final categories depend on the site's approved risk assessment and inspection scope. The examples below are not a universal required set.
A useful set is more than a collection of defective units. Intended use, traceability, status, handling, storage, change, and retirement should be defined.
These answers distinguish regulatory expectations from site-defined study choices. Project-specific protocols and acceptance criteria remain the customer's responsibility.
No. Knapp-style comparative inspection is an industry methodology. Applicable regulations and compendial texts establish broader expectations; the site's study design and acceptance criteria still require scientific justification and approval.
No universal value applies to every product, container, defect population, and intended use. The protocol should justify its population, repetitions, metrics, acceptance criteria, and statistical confidence.
It should not be assumed. Formal studies need controlled, characterized, blinded, and lifecycle-managed units. The site's procedure should define independence and prior-exposure controls.
Source status: Applicable requirements depend on product, market, and intended use. Relevant starting points include FDA's draft guidance on visible particles, EU GMP Annex 1, and current USP chapters <790> and <1790>. FDA's document remains draft guidance; USP <1790> is informational. Confirm current licensed texts and market requirements before approving a protocol.
Share your fill volume, product appearance, viscosity, inspection method, defect categories, documentation needs, and target timeline. The quote form now captures those project inputs directly.